Wockhardt News and Updates

Keep track of all breaking news on Wockhardt from all sources in a single place.

Load latest

Wockhardt Ltd.

04 May 2026

2179.40

-1.86%

to see Rapid results content

Wockhardt Ltd.

10 Feb 2026, 03:15PM

2179.40

-1.86%

to see Rapid results content

Wockhardt Ltd.

02 Dec 2025

2179.40

-1.86%

'Expect Large Revenue': Wockhardt Ready To Break Out Of Current Range After Historic USFDA Nod For Zaynich

NDTV Profit

Wockhardt is confident about breaking out of the current Rs 3,000-3,500 crore revenue range, even stating that FY28 could be a pivotal year for the company.

Number of FII/FPI investors increased from 180 to 198 in Jun 2026 qtr.

Wockhardt shares extend rally as USFDA accepts NDA for antibiotic Zaynich

Business Line | 02 Dec 2025 4 more

Wockhardt Ltd.

03 Nov 2025

2179.40

-1.86%

to see Rapid results content

Wockhardt Ltd.

01 Oct 2025

2179.40

-1.86%

Wockhardt files new drug application with USFDA for antibacterial drug

Business Standard

Drug firm Wockhardt on Wednesday said it has submitted a new drug application for its novel antibacterial drug with the US health regulator. The company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (USFDA) for its novel antibacterial agent Zidebactam-Cefepime injection, the Mumbai-based drugmaker said in a regulatory filing. The NDA seeks approval for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, with or without concurrent bacteremia caused by Gram-negative bacteria, including multidrug-resistant (MDR), it added. In the US and EU, more than 8 million cases of cUTI are reported every year, reflecting the global burden of Gram-negative infections, the drug firm stated. "This milestone marks the first-ever NDA submission to the US FDA for a drug, fully discovered and developed by an Indian pharmaceutical company, a momentous achievement for Indian innovation," Wockhardt Ltd said. The NDA submission follows

Promoters unpledged 4.14% of shares in last quarter. Total pledge stands at 14.68% of promoter holdings

Wockhardt Ltd.

29 Sep 2025

2179.40

-1.86%

Wockhardt Rebounds From Friday's Slump; Stock Surges 9% Here's Why

NDTV Profit

Wockhardt Pharma was one of the worst hit pharma stocks in India following Trump's announcement, falling more than 9% in two trading sessions.

Wockhardt Ltd. is trading above all available SMAs

Wockhardt Ltd.

22 Sep 2025

2179.40

-1.86%

Indian drugmakers gear up for 600-800 cr insulin pen market post-Novo exit

Business Standard

Novo Nordisk to phase out insulin pens and cartridges in India; Eris, Wockhardt and Lupin prepare to capture Rs 600-800 crore market opportunity from FY26 onwards

Wockhardt has gained 39.71% in the last 1 Year

Wockhardt Ltd.

10 Sep 2025, 02:39PM

2179.40

-1.86%

Shukra Pharmaceuticals signs distribution pact with Wockhardt

Business Line

The tie-up permits Shukra Pharmaceuticals to quote products, collect order copies, raise invoices and collect payments directly on behalf of Wockhardt